Infiltrating bone marrow mesenchymal stem cells (BM-MSCs) increase prostate cancer cell invasion via altering the CCL5/HIF2a/androgen receptor signals

Oncotarget

Volumn 6, Issue 29, 2015, Pages 27555-27565

  Luo, Jie ^a,b   Lee, Soo Ok ^a,b   Cui, Yun ^a,b   Yang, Rachel ^a,b   Li, Lei ^a,b,c   Chang, Chawnshang ^a,b,d  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Androgen receptor; Bone marrow mesenchymal stem cells; CCL5; HIF2a; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CD133 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MESSENGER RNA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROSTATE SPECIFIC ANTIGEN; RANTES; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR ZEB1; VON HIPPEL LINDAU PROTEIN; AR PROTEIN, HUMAN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CCL5 PROTEIN, HUMAN; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CANCER STEM CELL; CELL INFILTRATION; CELL POPULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; METASTASIS; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PROSTATE CANCER CELL LINE; PROSTATE METASTASIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; TUMOR INVASION; UBIQUITINATION; UPREGULATION; ANIMAL; BONE MARROW CELL; CANCER TRANSPLANTATION; CELL PROLIFERATION; CYTOLOGY; GENE EXPRESSION REGULATION; MESENCHYMAL STROMA CELL; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BONE MARROW CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CCL5; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANDROGEN; UBIQUITINATION;

EID: 84944474805     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4515     Document Type: Article

References (49)

1. Zhu P, Baek S.H, Bourk E.M, Ohgi K.A, Garcia-Bassets I, Sanjo H, Akira S, Kotol P.F, Glass C.K, Rosenfeld M.G, et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell. 2006; 124:615-629.
2. Zeng Y, Opeskin K, Goad J, Williams E.D. Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis. Cancer Res. 2006; 66:9566-9575.
3. Augsten M, Hagglof C, Olsson E, Stolz C, Tsagozis P, Levchenko T, Frederick M.J, Borg A, Micke P, Egevad L, et al. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci U S A. 2009; 106:3414-3419.
4. Quante M, Tu S.P, Tomita H, Gonda T, Wang S.S, Takashi S, Baik G.H, Shibata W, Diprete B, Betz K.S, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011; 19:257-272.
5. Kobayashi A, Okuda H, Xing F, Pandey P.R, Watabe M, Hirota S, Pai S.K, Liu W, Fukuda K, Chambers C, et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 2011; 208:2641-2655.
6. Ammirante M, Luo J.L, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 2010; 464:302-305.
7. Fang L.Y, Izumi K, Lai K.P, Liang L, Li L, Miyamoto H, Lin W.J, Chang C. Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling. Cancer Res. 2013; 73:5633-5646.
8. Izumi K, Mizokami A, Lin W.J, Lai K.P, Chang C. Androgen receptor roles in the development of benign prostate hyperplasia. Am J Pathol. 2013; 182:1942-1949.
9. Lin T.H, Izumi K, Lee S.O, Lin W.J, Yeh S, Chang C. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis. 2013; 4:e764.
10. Wang X, Lee S.O, Xia S, Jiang Q, Luo J, Li L, Yeh S, Chang C. Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-beta→MMP-9 signals. Mol Cancer Ther. 2013; 12:1026-1037.
11. Luo J, Ok Lee S, Liang L, Huang C.K, Li L, Wen S, Chang C. Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling. Oncogene. 2013.
12. Niu Y, Altuwaijri S, Lai K.P, Wu C.T, Ricke W.A, Messing E.M, Yao J, Yeh S, Chang C. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A. 2008; 105:12182-12187.
13. Niu Y, Chang T.M, Yeh S, Ma W.L, Wang Y.Z, Chang C. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene. 2010; 29:3593-3604.
14. Carter H.B. American Urological Association (AUA) Guideline on prostate cancer detection: process and rationale. BJU Int. 2013; 112:543-547.
15. Lin T.H, Lee S.O, Niu Y, Xu D, Liang L, Li L, Yeh S.D, Fujimoto N, Yeh S, Chang C. Differential Androgen Deprivation Therapies with Anti-androgens Casodex/Bicalutamide or MDV3100/Enzalutamide versus Anti-androgen Receptor ASC-J9(R) Lead to Promotion versus Suppression of Prostate Cancer Metastasis. J Biol Chem. 2013; 288:19359-19369.
16. Poon E, Harris A.L, Ashcroft M. Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med. 2009; 11:e26.
17. Haddad N.M, Cavallerano J.D, Silva P.S. Von hippel-lindau disease: a genetic and clinical review. Semin Ophthalmol. 2013; 28:377-386.
18. Semenza G.L. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012; 33:207-214.
19. Brahimi-Horn M.C, Pouyssegur J. HIF at a glance. J Cell Sci. 2009; 122:1055-1057.
20. Huang L.E, Bunn H.F. Hypoxia-inducible factor and its biomedical relevance. J Biol Chem. 2003; 278:19575-19578.
21. Greijer A.E, van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol. 2004; 57:1009-1014.
22. Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell. 2011; 8:486-498.
23. Kleinman, H.K., Jacob, K. Invasion assays. Curr Protoc Cell Biol Chapter. 2001; 12:Unit 12 12.
24. Koh M.Y, Lemos R Jr, Liu X, Powis G. The hypoxia-associated factor switches cells from HIF-1alpha-to HIF-2alpha-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res. 2011; 71:4015-4027.
25. Mimeault M, Batra S.K. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer-and metastasis-initiating cells. J Cell Mol Med. 2013; 17:30-54.
26. Lee S.O, Ma Z, Yeh C.R, Luo J, Lin T.H, Lai K.P, Yamashita S, Liang L, Tian J, Li L, et al. New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells. J Mol Cell Biol. 2013; 5:14-26.
27. Sen Banerjee S, Thirunavukkarasu M, Tipu Rishi M, Sanchez J.A, Maulik N, Maulik G. HIF-prolyl hydroxylases and cardiovascular diseases. Toxicol Mech Methods. 2012; 22:347-358.
28. Rankin E.B, Biju M.P, Liu Q, Unger T.L, Rha J, Johnson R.S, Simon M.C, Keith B, Haase V.H. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest. 2007; 117:1068-1077.
29. Maxwell P.H, Wiesener M.S, Chang G.W, Clifford S.C, Vaux E.C, Cockman M.E, Wykoff C.C, Pugh C.W, Maher E.R, Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399:271-275.
30. Chang C.S, Kokontis J, Liao S.T. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science. 1988; 240:324-326.
31. Heinlein C.A, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004; 25:276-308.
32. Wen S, Niu Y, Lee S.O, Chang C. Androgen Receptor (AR) Positive vs Negative Roles in Prostate Cancer Cell Deaths including Apoptosis, Anoikis, Entosis, Necrosis and Autophagic Cell Death. Cancer Treatment Reviews 2014; 40:31-40.
33. Niu Y, Altuwaijri S, Yeh S, Lai K.P, Yu S, Chuang K.H, Huang S.P, Lardy H, Chang C. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci U S A. 2008; 105:12188-12193.
34. Lai K.P, Huang C.K, Chang Y.J, Chung C.Y, Yamashita S, Li L, Lee S.O, Yeh S, Chang C. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol. 2013; 182:460-473.
35. Yamashita S, Lai K.P, Chuang K.L, Xu D, Miyamoto H, Tochigi T, Pang S.T, Li L, Arai Y, Kung H.J, et al. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia. 2012; 14:74-83.
36. Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Stokke T, Nesland J.M, Suo Z. Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS One. 2011; 6:e29170.
37. Fang Y, Fliss A.E, Robins D.M, Caplan A.J. Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem. 1996; 271:28697-28702.
38. Karnoub A.E, Dash A.B, Vo A.P, Sullivan A, Brooks M.W, Bell G.W, Richardson A.L, Polyak K, Tubo R, Weinberg R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007; 449:557-563.
39. Ye H, Cheng J, Tang Y, Liu Z, Xu C, Liu Y, Sun Y. Human bone marrow-derived mesenchymal stem cells produced TGFbeta contributes to progression and metastasis of prostate cancer. Cancer Invest. 2012; 30:513-518.
40. Maher E.R. HIF2 and endocrine neoplasia: an evolving story. Endocr Relat Cancer. 2013; 20:C5-7.
41. Pawlus M.R, Hu C.J. Enhanceosomes as integrators of hypoxia inducible factor (HIF) and other transcription factors in the hypoxic transcriptional response. Cell Signal. 2013; 25:1895-1903.
42. Kimbro K.S, Simons J.W. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer. 2006; 13:739-749.
43. Amankwah E.K, Sellers T.A, Park J.Y. Gene variants in the angiogenesis pathway and prostate cancer. Carcinogenesis. 2012; 33:1259-1269.
44. Heinlein C.A, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev. 2002; 23:175-200.
45. Hammerer P, Madersbacher S. Landmarks in hormonal therapy for prostate cancer. BJU Int. 2012; 110:23-29.
46. Tsao C.K, Galsky M.D, Small A.C, Yee T, Oh W.K. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). BJU Int. 2012; 110:1580-1588.
47. Miyamoto H, Messing E.M, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate. 2004; 61:332-353.
48. Miyamoto H, Messing E.M, Chang C. Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer? Nat Clin Pract Oncol. 2005; 2:236-237.
49. Miyamoto H, Altuwaijri S, Cai Y, Messing E.M, Chang C. Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Mol Carcinog. 2005; 44:1-10.